 Bradley Corr
Concepts (217)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 22 | 2025 | 208 | 6.870 |
Why?
| | Ovarian Neoplasms | 14 | 2025 | 586 | 3.050 |
Why?
| | Neoplasm Recurrence, Local | 10 | 2025 | 1137 | 2.350 |
Why?
| | beta Catenin | 5 | 2025 | 252 | 2.070 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 14 | 2025 | 1953 | 1.850 |
Why?
| | Carcinoma, Endometrioid | 3 | 2022 | 51 | 1.760 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 3 | 2025 | 132 | 1.660 |
Why?
| | Antibodies, Monoclonal, Humanized | 7 | 2025 | 985 | 1.400 |
Why?
| | Phenylurea Compounds | 4 | 2025 | 112 | 1.320 |
Why?
| | Quinolines | 4 | 2025 | 193 | 1.260 |
Why?
| | Wnt Signaling Pathway | 3 | 2025 | 210 | 0.920 |
Why?
| | Phthalazines | 1 | 2025 | 64 | 0.890 |
Why?
| | Lymph Nodes | 2 | 2018 | 502 | 0.850 |
Why?
| | Uterine Cervical Neoplasms | 6 | 2024 | 267 | 0.800 |
Why?
| | Piperazines | 1 | 2025 | 381 | 0.770 |
Why?
| | Indoles | 1 | 2025 | 501 | 0.680 |
Why?
| | Wnt Proteins | 1 | 2021 | 133 | 0.640 |
Why?
| | Aged, 80 and over | 23 | 2025 | 8265 | 0.630 |
Why?
| | Tumor Suppressor Protein p53 | 5 | 2025 | 529 | 0.600 |
Why?
| | Mutation | 6 | 2025 | 4089 | 0.590 |
Why?
| | Camptothecin | 3 | 2025 | 140 | 0.590 |
Why?
| | Immunoconjugates | 3 | 2025 | 132 | 0.590 |
Why?
| | Female | 49 | 2025 | 78271 | 0.530 |
Why?
| | Drug Resistance, Neoplasm | 7 | 2025 | 881 | 0.510 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2018 | 76 | 0.500 |
Why?
| | Practice Patterns, Physicians' | 2 | 2025 | 1356 | 0.500 |
Why?
| | Antineoplastic Agents | 5 | 2025 | 2194 | 0.490 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2020 | 64 | 0.480 |
Why?
| | Middle Aged | 33 | 2025 | 35875 | 0.470 |
Why?
| | Keratin-5 | 1 | 2015 | 48 | 0.460 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2015 | 49 | 0.450 |
Why?
| | Venous Thromboembolism | 2 | 2020 | 324 | 0.450 |
Why?
| | Cisplatin | 2 | 2023 | 334 | 0.440 |
Why?
| | Aged | 28 | 2025 | 25913 | 0.440 |
Why?
| | Hysterectomy | 4 | 2019 | 137 | 0.420 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2013 | 62 | 0.400 |
Why?
| | Humans | 53 | 2025 | 144759 | 0.390 |
Why?
| | Neoplasm Grading | 4 | 2025 | 307 | 0.380 |
Why?
| | Microsatellite Instability | 2 | 2025 | 54 | 0.370 |
Why?
| | Cholangiocarcinoma | 1 | 2013 | 105 | 0.370 |
Why?
| | Biomarkers, Tumor | 6 | 2025 | 1313 | 0.360 |
Why?
| | Bile Duct Neoplasms | 1 | 2013 | 127 | 0.360 |
Why?
| | Adult | 27 | 2025 | 40449 | 0.350 |
Why?
| | Cell Line, Tumor | 5 | 2025 | 3540 | 0.350 |
Why?
| | Cerebral Palsy | 2 | 2025 | 132 | 0.350 |
Why?
| | Genital Neoplasms, Female | 3 | 2024 | 99 | 0.340 |
Why?
| | Lymph Node Excision | 3 | 2018 | 173 | 0.340 |
Why?
| | Molecular Targeted Therapy | 2 | 2025 | 432 | 0.310 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2025 | 1455 | 0.280 |
Why?
| | Maytansine | 2 | 2025 | 18 | 0.270 |
Why?
| | Pyrimidinones | 2 | 2025 | 126 | 0.260 |
Why?
| | Immunotherapy | 3 | 2025 | 653 | 0.260 |
Why?
| | Bevacizumab | 3 | 2025 | 167 | 0.250 |
Why?
| | Immunohistochemistry | 2 | 2023 | 1716 | 0.240 |
Why?
| | Sensorimotor Cortex | 1 | 2025 | 8 | 0.230 |
Why?
| | Homologous Recombination | 1 | 2025 | 36 | 0.230 |
Why?
| | Maintenance Chemotherapy | 1 | 2025 | 42 | 0.230 |
Why?
| | Cell Survival | 2 | 2021 | 1098 | 0.230 |
Why?
| | CTLA-4 Antigen | 1 | 2025 | 104 | 0.220 |
Why?
| | Drug Synergism | 1 | 2025 | 357 | 0.220 |
Why?
| | Folate Receptor 1 | 1 | 2024 | 17 | 0.220 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2025 | 928 | 0.220 |
Why?
| | Uterine Neoplasms | 1 | 2025 | 96 | 0.210 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2025 | 84 | 0.210 |
Why?
| | Tryptophan Oxygenase | 1 | 2024 | 33 | 0.210 |
Why?
| | Pyrazoles | 3 | 2025 | 509 | 0.200 |
Why?
| | DNA Polymerase II | 2 | 2023 | 35 | 0.200 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 2 | 2023 | 36 | 0.200 |
Why?
| | Exercise Therapy | 2 | 2025 | 473 | 0.200 |
Why?
| | Gait | 1 | 2025 | 313 | 0.180 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 189 | 0.180 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2022 | 19 | 0.180 |
Why?
| | Neoplasms | 3 | 2022 | 2875 | 0.170 |
Why?
| | Thrombocytopenia | 1 | 2023 | 205 | 0.170 |
Why?
| | Radiosurgery | 1 | 2025 | 400 | 0.170 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2021 | 44 | 0.170 |
Why?
| | Indazoles | 1 | 2021 | 80 | 0.160 |
Why?
| | Retrospective Studies | 7 | 2025 | 17066 | 0.160 |
Why?
| | Disease Progression | 3 | 2025 | 2847 | 0.160 |
Why?
| | Precision Medicine | 1 | 2025 | 457 | 0.160 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2020 | 52 | 0.160 |
Why?
| | DNA Mismatch Repair | 3 | 2025 | 52 | 0.160 |
Why?
| | Benzoxazoles | 1 | 2020 | 20 | 0.160 |
Why?
| | Double-Blind Method | 1 | 2025 | 2029 | 0.160 |
Why?
| | Neoplasm Staging | 3 | 2019 | 1462 | 0.160 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2023 | 549 | 0.160 |
Why?
| | Imidazoles | 1 | 2021 | 254 | 0.150 |
Why?
| | Azepines | 1 | 2020 | 107 | 0.150 |
Why?
| | Enoxaparin | 1 | 2020 | 67 | 0.150 |
Why?
| | Disease Susceptibility | 1 | 2021 | 348 | 0.150 |
Why?
| | Machine Learning | 1 | 2025 | 585 | 0.150 |
Why?
| | Mindfulness | 1 | 2021 | 155 | 0.140 |
Why?
| | Survival Analysis | 3 | 2020 | 1382 | 0.140 |
Why?
| | Margins of Excision | 1 | 2019 | 51 | 0.140 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2019 | 108 | 0.140 |
Why?
| | Pyridones | 1 | 2020 | 199 | 0.140 |
Why?
| | Frozen Sections | 1 | 2018 | 24 | 0.130 |
Why?
| | Recurrence | 1 | 2021 | 1135 | 0.130 |
Why?
| | PTEN Phosphohydrolase | 1 | 2019 | 164 | 0.130 |
Why?
| | Oncologists | 1 | 2018 | 46 | 0.130 |
Why?
| | Protein Kinase Inhibitors | 2 | 2023 | 969 | 0.130 |
Why?
| | Colorectal Neoplasms | 1 | 2025 | 845 | 0.130 |
Why?
| | Preoperative Care | 2 | 2017 | 379 | 0.130 |
Why?
| | Postural Balance | 1 | 2020 | 240 | 0.130 |
Why?
| | Cohort Studies | 4 | 2025 | 5960 | 0.130 |
Why?
| | Cross-Sectional Studies | 3 | 2018 | 5868 | 0.130 |
Why?
| | Disease Management | 1 | 2021 | 645 | 0.130 |
Why?
| | Pyridines | 1 | 2021 | 605 | 0.120 |
Why?
| | Pyrimidines | 1 | 2020 | 532 | 0.120 |
Why?
| | Minority Groups | 1 | 2018 | 282 | 0.120 |
Why?
| | Amyotrophic Lateral Sclerosis | 3 | 2003 | 99 | 0.120 |
Why?
| | Gynecology | 1 | 2018 | 178 | 0.120 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 50 | 0.120 |
Why?
| | Perioperative Period | 1 | 2015 | 71 | 0.110 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 508 | 0.110 |
Why?
| | Anticoagulants | 1 | 2020 | 722 | 0.110 |
Why?
| | Radiography, Thoracic | 1 | 2016 | 171 | 0.110 |
Why?
| | Laparotomy | 1 | 2015 | 112 | 0.110 |
Why?
| | Heparin | 1 | 2015 | 244 | 0.100 |
Why?
| | Surgeons | 1 | 2018 | 339 | 0.100 |
Why?
| | Disease Models, Animal | 1 | 2024 | 4557 | 0.100 |
Why?
| | Platinum | 2 | 2025 | 50 | 0.100 |
Why?
| | Quality of Health Care | 1 | 2018 | 691 | 0.100 |
Why?
| | Magnetoencephalography | 2 | 2025 | 160 | 0.100 |
Why?
| | Treatment Outcome | 3 | 2020 | 11679 | 0.090 |
Why?
| | Receptors, Estrogen | 1 | 2015 | 457 | 0.090 |
Why?
| | Membrane Proteins | 1 | 2019 | 1166 | 0.090 |
Why?
| | Paclitaxel | 2 | 2025 | 255 | 0.090 |
Why?
| | Combined Modality Therapy | 2 | 2013 | 1266 | 0.090 |
Why?
| | Robotic Surgical Procedures | 1 | 2015 | 182 | 0.090 |
Why?
| | Ovary | 1 | 2013 | 228 | 0.090 |
Why?
| | Prognosis | 5 | 2023 | 4282 | 0.080 |
Why?
| | Case-Control Studies | 1 | 2019 | 3604 | 0.080 |
Why?
| | Maximum Tolerated Dose | 2 | 2022 | 212 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2024 | 2452 | 0.080 |
Why?
| | Young Adult | 6 | 2025 | 14105 | 0.080 |
Why?
| | Chemoradiotherapy | 2 | 2025 | 237 | 0.080 |
Why?
| | Postoperative Complications | 2 | 2020 | 2919 | 0.080 |
Why?
| | Mice | 2 | 2025 | 18339 | 0.080 |
Why?
| | Prospective Studies | 4 | 2023 | 7990 | 0.080 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 732 | 0.070 |
Why?
| | Cell Proliferation | 1 | 2015 | 2496 | 0.070 |
Why?
| | Animals | 3 | 2025 | 38058 | 0.070 |
Why?
| | Adolescent | 6 | 2025 | 22428 | 0.070 |
Why?
| | Apoptosis | 1 | 2015 | 2430 | 0.060 |
Why?
| | Genomic Instability | 1 | 2025 | 66 | 0.060 |
Why?
| | Retreatment | 1 | 2025 | 77 | 0.060 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2025 | 45 | 0.060 |
Why?
| | GPI-Linked Proteins | 1 | 2025 | 80 | 0.050 |
Why?
| | Carboplatin | 1 | 2025 | 160 | 0.050 |
Why?
| | Carbonyl Reductase (NADPH) | 1 | 2024 | 5 | 0.050 |
Why?
| | Wnt4 Protein | 1 | 2024 | 20 | 0.050 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2025 | 264 | 0.050 |
Why?
| | Cell Adhesion Molecules | 1 | 2024 | 178 | 0.050 |
Why?
| | Kynurenine | 1 | 2024 | 114 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2025 | 769 | 0.050 |
Why?
| | Mesylates | 1 | 2022 | 7 | 0.050 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2022 | 19 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2024 | 271 | 0.050 |
Why?
| | Tryptophan | 1 | 2024 | 181 | 0.050 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2024 | 190 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2637 | 0.050 |
Why?
| | Registries | 3 | 2018 | 2385 | 0.040 |
Why?
| | Ligands | 1 | 2024 | 673 | 0.040 |
Why?
| | Somatosensory Cortex | 1 | 2022 | 42 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2024 | 241 | 0.040 |
Why?
| | Antibodies, Bispecific | 1 | 2022 | 64 | 0.040 |
Why?
| | Ambulatory Care Facilities | 1 | 2003 | 265 | 0.040 |
Why?
| | Quality of Life | 2 | 2025 | 3185 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2024 | 824 | 0.040 |
Why?
| | Decision Trees | 1 | 2000 | 81 | 0.040 |
Why?
| | Aurora Kinase A | 1 | 2020 | 62 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 63 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2024 | 780 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 139 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2022 | 557 | 0.040 |
Why?
| | Physical Examination | 1 | 2020 | 239 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2025 | 1720 | 0.030 |
Why?
| | Patient Care Team | 1 | 2003 | 689 | 0.030 |
Why?
| | Adenine | 1 | 2020 | 339 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2020 | 688 | 0.030 |
Why?
| | Ireland | 3 | 2003 | 32 | 0.030 |
Why?
| | Program Evaluation | 1 | 2021 | 948 | 0.030 |
Why?
| | Walking | 1 | 2022 | 545 | 0.030 |
Why?
| | Physical Therapy Modalities | 1 | 2020 | 332 | 0.030 |
Why?
| | Regression Analysis | 1 | 2019 | 1003 | 0.030 |
Why?
| | Macrophages | 1 | 2024 | 1511 | 0.030 |
Why?
| | Brain Neoplasms | 1 | 2025 | 1318 | 0.030 |
Why?
| | Neoadjuvant Therapy | 1 | 2018 | 462 | 0.030 |
Why?
| | RNA | 1 | 2022 | 940 | 0.030 |
Why?
| | Ileus | 1 | 2015 | 13 | 0.030 |
Why?
| | Salpingectomy | 1 | 2015 | 15 | 0.030 |
Why?
| | Urinary Retention | 1 | 2015 | 25 | 0.030 |
Why?
| | Ovariectomy | 1 | 2015 | 162 | 0.030 |
Why?
| | Blood Loss, Surgical | 1 | 2015 | 112 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2089 | 0.030 |
Why?
| | Pelvis | 1 | 2015 | 124 | 0.030 |
Why?
| | Logistic Models | 1 | 2018 | 2117 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1694 | 0.020 |
Why?
| | Caregivers | 1 | 2021 | 1049 | 0.020 |
Why?
| | Patient Readmission | 1 | 2018 | 758 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2018 | 5408 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2018 | 851 | 0.020 |
Why?
| | United States | 2 | 2019 | 15966 | 0.020 |
Why?
| | Signal Transduction | 1 | 2024 | 5226 | 0.020 |
Why?
| | Male | 5 | 2025 | 72315 | 0.020 |
Why?
| | Length of Stay | 1 | 2015 | 1337 | 0.020 |
Why?
| | Immunotherapy, Adoptive | 1 | 2012 | 337 | 0.020 |
Why?
| | Patient Discharge | 1 | 2015 | 983 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2003 | 1489 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 3333 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1519 | 0.010 |
Why?
| | Interprofessional Relations | 1 | 2003 | 281 | 0.010 |
Why?
| | Child | 1 | 2020 | 22633 | 0.010 |
Why?
| | Central Nervous System Diseases | 1 | 2000 | 74 | 0.010 |
Why?
| | Age of Onset | 1 | 2000 | 551 | 0.010 |
Why?
| | Palliative Care | 1 | 2003 | 1002 | 0.010 |
Why?
|
|
Corr's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|